Pulse Biosciences completes 100-patient enrollment in PRECISE-BTN thyroid nodule study

PULSE BIOSCIENCES, INC.

PRECISE-BTN study of nPulse Vybrance system fully enrolled 100 patients (expanded from original 50) by August 2026.
First enrolled patient completed final 12-month follow-up in August at Sarasota Memorial Health Care System.
Patients enrolled across three U.S. sites: Sarasota Memorial, NYU Langone Health, Weill Cornell Medicine in about 12 months.
Preliminary data expected at upcoming medical conference; full data after all patients complete 12-month follow-up.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.